-+ 0.00%
-+ 0.00%
-+ 0.00%

*Arcutis On Track to Disclose Topline Results From Phase 2 Trial of ZORYVE Foam 0.3% in Individuals With Vitiligo and Decision on Program Advancement in 4Q

Dow Jones·11/04/2026 21:25:00

Please log in to view news